At BioPortUSA and MC2 MedTech Commercial Consulting, we’ve come together to offer medtech companies a full spectrum of solutions designed to drive success at every stage of their journey.[...]
At BioPortUSA and MC2 MedTech Commercial Consulting, we’ve come together to offer medtech companies a full spectrum of solutions designed to drive success at every stage of their journey.[...]
BioPortUSA is excited to announce its recent membership with LifeSciencesNY, a prominent New York-based association committed to fostering innovation and driving growth in the state’s thriving bio/med industry. By becoming part of this influential organization, BioPortUSA is joining a network of professionals and companies who share a common goal: making New York a leader in cutting-edge healthcare technology. LifeSciencesNY is dedicated to promoting the life sciences ecosystem in New York, offering tools, programs, and networking opportunities that empower its members to bring groundbreaking medical solutions to market. Through its initiatives, LifeSciencesNY plays a crucial role in helping bio/med companies overcome regulatory, financial, and operational hurdles, ensuring that innovation is not only nurtured but also successfully commercialized.[...]
BioPortUSA was recently hired to help French firm BOYDSense with their commercialization process. The first step was to help develop a regulatory pathway which would tell us how to proceed with pursuing FDA clearance. While the focus is on diabetes today, the underlying technology has the possibility of screening for other diseases including cancer. [...]
Human in Motion Robotics (HMR), a cutting-edge robotics company based in Vancouver, Canada, recently sought the expertise of BioPortUSA to guide them through the complexities of entering the U.S. healthcare market. Specializing in advanced exoskeleton technology, HMR has been pushing the boundaries of mobility solutions, driven by a vision to offer people with limited mobility a more independent and empowered future.[...]
The German Healthcare Alliance (GHA) has invited, Mark Lesselroth, CEO of BioPortUSA to speak at their inaugural event on April 16 on what it takes to be successful in the U.S. healthcare market. The GHA consists of more than 100 leading German actors virtually from all sectors: private sector and industry, NGOs, civil society and foundations, science and academia.[...]
Mark Lesselroth, CEO of BioPortUSA was recently interviewed by Katharina Kort, the Washington D.C. Bureau Chief for the Handelsblatt, Germany’s most prestigious business newspaper. A few prominent examples in recent years have shown how difficult the US market can be for German companies: Sometimes the choice of location and product is not right, as is the case with the retailer Lidl , which has problems convincing Americans of its stores. Sometimes the legal risks are much higher than expected, as Bayer found out with Monsanto. And cultural differences are often underestimated, as the failed Daimler- Chrysler merger showed many years ago.[...]
BioPortUSA to attend Messe Düsseldorf/Medica networking breakfast event. [...]
Mark Lesselroth, president and CEO of BioPortUSA has been invited by the organizers of the Medica Program Committee to talk about how to successfully enter the U.S. Healthcare Market.[...]
Social Media